Browse studies

Find your next paid study

1,058 recruiting studies matching your filters

Supporting Health Including Endocrine Treatment for Long Duration: A Pilot Intervention

This research is being done to pilot an intervention which aims to test a new web- and mobile application ("app")-based supportive care tool (SHIELD portal) an…

Breast CancerBreast Cancer - FemaleBreast Carcinoma+2 more

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT07482384

Phase 1

A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-023 as a Single Agent, and in Combination With AVZO-021 and/or Endocrine Therapy in Patients With Advanced Solid Tumors

This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, …

HR+/HER2- Breast CancerHR+, HER2-, Advanced Breast Cancer

Estimated

~$10 – $8,750

Avenzo Therapeutics, Inc.NCT06998407

Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue

To create a registry (database) of participants who come in for breast MRI scans. Researchers want to use this information to study if participants with dense …

Breast Cancer

Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT06127797

Observational

Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics

To identify Black individuals who are eligible for genetic testing through trusted community organizations, and to connect Black individuals and their families…

Breast CancerColorectal Cancer

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT05694559

Phase 1

A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.

Advanced Breast Cancer

Estimated

~$10 – $8,750

Stemline Therapeutics, Inc.NCT06638307

Observational

Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery: An International, Randomized Superiority Trial (OPBC-10/ NOAX)

This trial is to investigate if in patients with clinically node positive breast cancer undergoing upfront surgery, treatment with TAS and ART is superior to A…

Breast Cancer

Estimated

~$10 – $6,250

University Hospital, Basel, SwitzerlandNCT07140172

Phase 2

Evaluation of Prostate Specific Membrane Antigen (PSMA) in HER2-negative, Androgen Receptor (AR)-Positive Metastatic Breast Cancer With 18F-DCFPyL PSMA-based PET/CT

The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-neg…

Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer

Estimated

~$10 – $6,250

University of Wisconsin, MadisonNCT04573231

Phase 2

A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer: The SAPPHO Study

The purpose of this study is to test the safety and effectiveness of a sequence of drugs (a Taxane plus Trastuzumab plus Pertuzumab followed by Trastuzumab Der…

Breast Cancer FemaleBreast CancerBreast Cancer Metastatic+3 more

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT06439693

Phase 3

A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu…

Breast Cancer

Estimated

~$10 – $8,750

Greenwich LifeSciences, Inc.NCT05232916

Observational

Accuracy and Effect of Prescribed Generative AI Patient Education Module Within Breast Oncology Care

This study evaluates the safety, accuracy, and impact of an artificial intelligence (AI) tool designed to support patient education in breast cancer care for b…

Breast CancerMetastatic Breast CancerCarcinoma of the Breast

Estimated

~$10 – $5,625

University of California, San FranciscoNCT07512271

Phase 2

Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation for Participants With Ipsilateral Breast Tumor Recurrence Treated Initially With Breast Conserving Surgery and Whole Breast Radiation Therapy

The standard treatment for participants whose cancer has returned after breast conserving surgery is radiation given twice daily (separated by at least 6 hours…

Breast CancerTumor, Breast

Estimated

~$10 – $6,250

Case Comprehensive Cancer CenterNCT06129747

Phase 1

Evaluation of PSMA Expression in Triple Negative Breast Cancer Patients Using 18 F-DCFPyL-PET/CT

The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) pati…

Triple Negative Breast Cancer

Estimated

~$10 – $7,500

Ahmad ShariftabriziNCT06586047